Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, …
Full AMRN analysis →
Competitive advantage assessment
Key strengths
Strong Liquidity BufferLiquidity position is strong (score 1.00), providing operational cushion.
Key risks
Commodity Pressure / Weak DifferentiationGross margin at 15.8th percentile with high volatility suggests weak pricing power or commoditized products.
Below-Peer Operating EfficiencyOperating margin at 15.8th percentile indicates below-peer efficiency.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Amarin Corporation plc ranks #19 of 20
scored companies in Drug Manufacturers - General by moat score — the top 95%.
The widest moat in the group is Novo Nordisk A/S (NVO)
at 74/100.
Moat scores for companies ranked near AMRN in Drug Manufacturers - General
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 16
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 19
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 36
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 34
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 18
· 15% of the moat score
Scale matters only when it converts into economics.
Amarin Corporation plc (AMRN) scores 23 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #19 of 20 scored companies in Drug Manufacturers - General, the top 95%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 19 companies in Drug Manufacturers - General. Its strongest defense is Capital Efficiency (36/100) and its weakest is Pricing Power (15/100).
How does Amarin Corporation plc compare with other Drug Manufacturers - General companies?
Amarin Corporation plc ranks #19 of 20 scored companies in Drug Manufacturers - General by moat score. The widest moat in Drug Manufacturers - General is Novo Nordisk A/S (NVO) at 74/100. The companies ranked closest are Scilex Holding Company (SCLXW) at 26 just above it and MIRA Pharmaceuticals, Inc. (MIRA) at 15 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 19 companies in Drug Manufacturers - General. The defenses are then weighted to produce the overall score out of 100.
Why is Amarin Corporation plc scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Amarin Corporation plc?
The Corporate Default template measures 6 defenses, and AMRN scores: Pricing Power (15), Cost Advantage (16), Customer Stickiness (19), Capital Efficiency (36), Resilience (34), Scale & Market Position (18). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.